No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial

• Chizoba C. Umeh ,

  * E-mail: cumeh@partners.org

  Affiliation Department of Neurology and Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

  ⨯
• Adriana Pérez,

  Affiliation Department of Biostatistics, The University of Texas School of Public Health, Austin, Texas, United States of America

  ⨯
• Erika F. Augustine,

  Affiliation Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America

  ⨯
• Rohit Dhall,

  Affiliation Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States of America

  ⨯
• Richard B. Dewey Jr.,

  Affiliation Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

  ⨯
• Zoltan Mari,

  Affiliation Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• David K. Simon,

  Affiliation Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Anne-Marie A. Wills,

  Affiliation Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America

  ⨯
• Chadwick W. Christine,

  Affiliation Department of Neurology, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Jay S. Schneider,

  Affiliation Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

  ⨯
• Oksana Suchowersky

  Affiliation Departments of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada

  ⨯